Diabetes therapy with GLP-1-based drugs does not elevate the risk of IBD

Diabetes therapy with GLP-1-based drugs does not elevate the risk of IBD

Presented By

Dr Heidi Søgaard Christensen , Aalborg University Hospital, Denmark

Conference

ECCO 2023

4 May, 2023 16:59

Long-term resection potentially better than anti-TNF treatment in CD

Presented By

Prof. Manasi Agrawal, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

LIR!C

Conference

ECCO 2023

4 May, 2023 16:58

Early, post-operative complications in CD reduced by pre-operative enteral nutrition, irrespective of biologic exposure

Presented By

Prof. Mathurin Fumery, Amiens University Hospital, France

Conference

ECCO 2023

4 May, 2023 16:55

Perinatal period is crucial for the risk of developing CD

Presented By

Prof. Sun-Ho Lee, Mount Sinai Hospital, Canada

Conference

ECCO 2023

4 May, 2023 16:53

Drop in overall IBD procedures during the pandemic

Presented By

Dr M Derks Eduarda Wilhelmina, Radboud University Medical Centre, the Netherlands

Conference

ECCO 2023

4 May, 2023 16:46

Early-life antibiotic exposure: a risk factor for paediatric-onset IBD

Presented By

Dr Mikkel Malham, Copenhagen University Hospital, Denmark

Conference

ECCO 2023

4 May, 2023 16:46

Proton pump inhibitors associated with worse outcomes in CD

Presented By

Dr Stéphanie Barrau, Saint Etienne University Hospital, France

Conference

ECCO 2023

4 May, 2023 16:42

Paediatric patients with immune-mediated inflammatory disease harbour a heightened cancer risk

Presented By

Ms Andrea Ehrström , Hvidovre Hospital, Denmark

Conference

ECCO 2023

4 May, 2023 16:40

Poor sleep in CD linked to low levels of vitamin D

Presented By

Dr Caroline Walker, Tallaght University Hospital, Ireland

Conference

ECCO 2023

4 May, 2023 16:38

Beneficial effect of early, post-operative vedolizumab on endoscopic recurrence in CD

Presented By

Prof. Geert D’Haens , Academic Medical Center University of Amsterdam, the Netherlands

Trial

REPREVIO

Conference

ECCO

4 May, 2023 16:28

Long-term data supports the established efficacy and safety of ustekinumab in UC

Presented By

Prof. Silvio Danese , Vita-Salute San Raffaele University, Italy

Trial

UNIFI LTE UNIFI LTE

Conference

ECCO 2023

4 May, 2023 16:21

Fast recapture of response with ozanimod after withdrawal in UC

Presented By

Dr Anita Afzali, University of Cincinnati College of Medicine, OH, USA

Trial

Phase 3, True North

Conference

UEGW 2022

1 December, 2022 22:08

Ozanimod treatment prompted substantial response after failure of response to induction

Presented By

Prof. Remo Panaccione, University of Calgary, Canada

Trial

Phase 3, True North

Conference

UEGW 2022

1 December, 2022 22:06

Etrasimod shows advantage over placebo in UC

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, ELEVATE UC

Conference

UEGW 2022

1 December, 2022 22:03

Etrasimod reduces adaptive immune cells in the periphery in UC

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, ELEVATE UC

Conference

UEGW 2022

1 December, 2022 22:00

Favourable maintenance rates for risankizumab also in delayed responders with CD

Presented By

rof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 3, FORTIFY

Conference

UEGW 2022

1 December, 2022 21:56

IL-23 inhibition reduces inflammatory biomarkers in pre-treated UC

Presented By

Prof. Julian Panés, Hospital Clínic Barcelona, Spain

Trial

Phase 2, QUASAR

Conference

UEGW 2022

1 December, 2022 21:53

Maintained symptom control with mirikizumab in UC

Presented By

Prof. Axel Dignass, Agaplesion Markus Hospital, Germany

Trial

Phase 3, LUCENT 2

Conference

UEGW 2022

1 December, 2022 21:49

Mirikizumab successfully resolves active histologic inflammation in UC

Presented By

Prof. Fernando Magro, CHU de São João, Portugal

Trial

Phase 2, LUCENT 2

Conference

UEGW 2022

1 December, 2022 21:44

Upadacitinib for CD: remarkable efficacy in induction therapy

Presented By

Prof. Julian Panés, Hospital Clínic Barcelona, Spain

Trial

Phase 3, U-EXCEL

Conference

UEGW 2022

1 December, 2022 21:42

Sustained maintenance results with upadacitinib in UC

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

U-ACHIEVE Maintenance

Conference

UEGW 2022

1 December, 2022 21:37

Start low with brepocitinib and ritlecitinib in UC

Presented By

Dr Kenneth Hung, Pfizer, MA, USA

Trial

Phase 2, VIBRATO

Conference

UEGW 2022

1 December, 2022 21:34

Another chance for TYK2 inhibition in UC

Presented By

Prof. Stephan Schreiber, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2, LATTICE-UC

Conference

UEGW 2022

1 December, 2022 21:29

Small molecule obefazimod shows promise in UC

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Conference

UEGW 2022

1 December, 2022 21:26

Pivotal results of etrolizumab for CD partly disappointing

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, BERGAMOT

Conference

UEGW 2022

1 December, 2022 17:27

Better results for vedolizumab in early CD

Presented By

Prof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 4, LOVE-CD

Conference

UEGW 2022

1 December, 2022 17:19

Some patients with limited CD may benefit from an early surgical intervention

Presented By

Dr Melek Zahra Sarikaya, Sjællands Universitetshospital, Denmark

Trial

LIR!C

Conference

UEGW 2022

1 December, 2022 17:11

Dose-interval of adalimumab might be prolonged in CD patients in stable remission

Presented By

Dr Reinier van Linschoten , Franciscus Gasthuis en Vlietland, the Netherlands

Trial

Phase 4, LADI

Conference

UEGW 2022

1 December, 2022 17:01

High prevalence of fibromyalgia in patients with inflammatory bowel disease

Presented By

Dr Laura Guida , Luigi Sacco University Hospital, Italy

Conference

EULAR 2022

21 July, 2022 19:27

Antibiotic use elevates IBD risks in senior citizens

Presented By

Prof. Adam S. Faye, NYU Langone Health, NY, USA

Conference

DDW 2022

14 June, 2022 22:22

Too much hygiene: CD in later life?

Presented By

Dr Williams Turpin, Mount Sinai Hospital and the University of Toronto, Canada

Conference

DDW 2022

14 June, 2022 22:18

Biologic treatment decreases dementia risk in senior IBD patients

Presented By

Dr Ahmed Eltelbany, Cleveland Clinic, OH, USA

Conference

DDW 2022

14 June, 2022 22:12

CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings

Presented By

Prof. Jean-Frederic Colombel, Mount Sinai Hospital, NY, USA

Trial

Phase 3, U-EXCEED

Conference

DDW 2022

14 June, 2022 22:07

IL-23 inhibition beneficial in maintenance treatment of UC

Presented By

Prof. Marla C. Dubinsky, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, LUCENT-2

Conference

DDW 2022

14 June, 2022 22:01

Positive outcomes for etrasimod in UC

Presented By

Prof. William J Sandborn, University of California San Diego, CA, USA

Trial

Phase 3, ELEVATE UC 12; ELEVATE UC 52

Conference

DDW 2022

14 June, 2022 21:53

Colonoscopy in UC: less pain and reduced recurrence with CO2 insufflation

Presented By

Dr Yuriko Otake, Osaka University

Conference

DDW 2022

14 June, 2022 18:21

Dermatology diseases need the highest doses of biologics

Presented By

Dr Charlotte Greif, Beth Israel Deaconess Medical Center, USA

Conference

AAD 2022

17 May, 2022 12:24

Lessons from the COVID-19 pandemic for IBD management

Presented By

Prof. Siew Ng, Chinese University of Hong Kong, Hong Kong

Conference

ECCO 2022

12 April, 2022 17:32

AI model distinguishes between histologic activity and remission in ulcerative colitis

Presented By

Dr Tommaso Parigi, Humanitas University, Italy

Trial

PICaSSO

Conference

ECCO 2022

12 April, 2022 17:29

Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors

Presented By

Dr Yael Haberman, Sheba Medical Center, Israel

Conference

ECCO 2022

12 April, 2022 17:27

Novel classification system for perianal fistulising Crohn’s disease

Presented By

Dr Philip Tozer, St Mark’s Hospital and Academic Institute, UK

Conference

ECCO 2022

12 April, 2022 17:26

Vaccination tool associated with improved vaccination coverage in IBD

Presented By

Ms Liselotte Fierens, KU Leuven, Belgium

Conference

ECCO 2022

12 April, 2022 17:24

Comparable safety profiles of biological therapies in elderly patients with IBD

Presented By

Dr Gustavo Drügg Hahn, McGill University Health Center, Canada

Conference

ECCO 2022

12 April, 2022 17:22

Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease

Presented By

Prof. Shomron Ben-Horin, Tel-Aviv University, Israel

Conference

ECCO 2022

12 April, 2022 17:21

RESTORE-UC: No better outcomes with FMT superdonors than with autologous stools

Presented By

Dr Clara Caenepeel, KU Leuven, Belgium

Trial

RESTORE-UC

Conference

ECCO 2022

12 April, 2022 17:17

Segmental colectomy beneficial over total colectomy in Chrohn’s disease

Presented By

Dr Gianluca Pellino, University of Campania Luigi Vanvitelli, Italy

Trial

SCOTCH

Conference

ECCO 2022

12 April, 2022 17:11

Similar results for different corticosteroid tapering protocols in UC

Presented By

Ms Pernille Ovesen, Herlev University Hospital, Denmark

Trial

SCOTCH

Conference

ECCO 2022

12 April, 2022 17:04

Ozanimod treatment shows maintained response in ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, True North

Conference

ECCO 2022

12 April, 2022 16:57

Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease

Presented By

Prof. Edouard Louis, University Hospital Liège, Belgium

Trial

Phase 4, SPARE

Conference

ECCO 2022

12 April, 2022 16:55

Vedolizumab first approved therapy for chronic pouchitis

Presented By

Prof. Simon Travis, University of Oxford, UK

Trial

Phase 4, EARNEST

Conference

ECCO 2022

12 April, 2022 16:53

VEDOKIDS: Vedolizumab seems effective in paediatric IBD

Presented By

Dr Dan Turner, Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Israel

Trial

VEDOKIDS

Conference

ECCO 2022

12 April, 2022 16:51

Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met

Presented By

Dr Marie Truyens, Ghent University Hospital, Belgium

Trial

Phase 2, Trp-IBD

Conference

ECCO 2022

12 April, 2022 16:48

Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease

Presented By

Dr Neeraj Narula, McMaster University, Canada

Conference

ECCO 2022

12 April, 2022 16:46

Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis

Presented By

Prof. Remo Panaccione , University of Calgary, Canada

Conference

ECCO 2022

12 April, 2022 16:44

Subcutaneous infliximab versus subcutaneous vedolizumab in IBD

Presented By

Prof. Laurent Peyrin-Biroulet, Nancy University Hospital, France

Conference

ECCO 2022

12 April, 2022 16:41

Vedolizumab outperforms anti-TNF in biologic-naïve ulcerative colitis

Presented By

Dr Bernd Bokemeyer, University Hospital Schleswig-Holstein, Germany

Trial

VEDO-IBD

Conference

ECCO 2022

12 April, 2022 16:37

Guselkumab shows encouraging safety and efficacy in ulcerative colitis

Presented By

Prof. Axel Dignass, Agaplesion Markus Hospital, Germany

Trial

Phase 2, QUASAR Induction

Conference

ECCO 2022

12 April, 2022 16:23

Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 2, GALAXI-1

Conference

ECCO 2022

12 April, 2022 16:21

Mirikizumab efficacious for active ulcerative colitis

Presented By

Prof. Geert D’Haens, Amsterdam University Medical Center, the Netherlands

Trial

Phase 3, LUCENT-1

Conference

ECCO 2022

12 April, 2022 16:18

Risankizumab more efficacious in colonic than in ileal Crohn’s disease

Presented By

Dr Peter Bossuyt, Imelda General Hospital, Belgium

Trial

Phase 3, ADVANCE, MOTIVATE, FORTIFY

Conference

ECCO 2022

12 April, 2022 16:15

Guselkumab plus golimumab promising combination for ulcerative colitis

Presented By

Prof. Bruce Sands, Mount Sinai School of Medicine, NY, USA

Trial

Phase 2, VEGA

Conference

ECCO 2022

12 April, 2022 16:10

Combined endpoint may support personalised medicine in ulcerative colitis

Presented By

Prof. Stefan Schreiber, Christian-Albrecht University, Germany

Trial

Phase 3, SELECTION

Conference

ECCO 2022

12 April, 2022 16:06

Filgotinib seems promising for perianal fistulising Crohn’s disease

Presented By

Dr Walter Reinisch, Medical University of Vienna, Austria

Trial

Phase 2, DIVERGENCE 2

Conference

ECCO 2022

12 April, 2022 16:04

Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, U-ACHIEVE

Conference

ECCO 2022

12 April, 2022 15:57

Upadacitinib counters extraintestinal manifestations in ulcerative colitis

Presented By

Prof. Jean-Frédéric Colombel, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, U-ACHIEVE; U-ACCOMPLISH

Conference

ECCO 2022

12 April, 2022 15:53

Upadacitinib effector pathways unravelled

Presented By

Dr Bram Verstockt, KU Leuven, Belgium

Trial

Phase 2, U-ACHIEVE

Conference

ECCO 2022

12 April, 2022 15:49

Deucravacitinib does not meet primary endpoint for ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 2, LATTICE-UC

Conference

ECCO 2022

12 April, 2022 15:43

Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease

Principal Investigator

Prof. Bruce E. Sands, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 2, SERENITY

Conference

UEGW 2020

2 November, 2020 12:20

Post-colonoscopy colorectal cancers in IBD patients

Presented By

Ms Frederikke S. Troelsen, Aarhus University Hospital, Denmark

Conference

UEGW 2020

2 November, 2020 11:19

Risk factors for severe COVID-19 among IBD patients

Presented By

Dr Ryan C. Ungaro, Icahn School of Medicine at Mount Sinai, USA

Trial

SECURE-IBD

Conference

UEGW 2020

2 November, 2020 11:13

Resolution of mucosal inflammation has dramatic effect

Presented By

Dr N. Plevris, Western General Hospital, Edinburgh, UK

Trial

Cohort study

Conference

ECCO 2020

14 April, 2020 16:15

Re-inducing inflammation in organoids from UC patients

Presented By

Dr K. Arnauts, Catholic University of Leuven, Belgium

Conference

ECCO 2020

14 April, 2020 16:07

Increased risk of small bowel cancer in IBD

Presented By

Dr J. Axelrad, New York University School of Medicine, New York, USA

Conference

ECCO 2020

14 April, 2020 15:53

Effects of vedolizumab versus adalimumab on QoL

Presented By

Dr E.V. Loftus, Mayo Clinic, USA

Trial

VARSITY

Conference

ECCO 2020

14 April, 2020 15:39

On the cutting edge of pathology and surgery

Presented By

Prof. P. B. Nunes & Prof. A. Spinelli

Conference

ECCO 2020

14 April, 2020 15:23

Impact of strategies on intestinal resection rate

Presented By

Dr D. Ley, University of Wisconsin–Madison, USA

Conference

ECCO 2020

14 April, 2020 15:16

Early ileocaecal resection in CD patients failing conventional treatment

Presented By

Dr T. Stevens, Amsterdam UMC, the Netherlands

Trial

LIR!C

Conference

ECCO 2020

14 April, 2020 15:11

Biologics before surgery in IBD do not elevate infection risk

Presented By

Dr S. Holubar, Cleveland Clinic, USA

Conference

ECCO 2020

14 April, 2020 15:06

Ustekinumab in CD: a T2T trial

Presented By

Prof. L. Peyrin-Biroulet, CHRU de Nancy, France

Trial

Phase 3, STARDUST

Conference

ECCO 2020

14 April, 2020 14:26

Subcutaneous ustekinumab as maintenance therapy in UC

Presented By

Dr R. Panaccione & Dr W.J. Sandborn

Trial

UNIFI

Conference

ECCO 2020

14 April, 2020 14:22

Vedolizumab treatment persistence and safety

Presented By

Dr S. Danese & Dr N.A. Cohen, Humanitas University, Milan, Italy

Trial

GEMINI

Conference

ECCO 2020

14 April, 2020 14:04

Pipeline of IBD drugs

Presented By

Prof. W. Sandborn, University of California San Diego, USA

Conference

ECCO 2020

14 April, 2020 13:55

Open-label extension study of risankizumab: final results

Presented By

Dr M. Ferrante, University Hospitals Leuven, Belgium

Conference

ECCO 2020

14 April, 2020 12:53

Clinical remission after dose escalation of upadacitinib

Presented By

Dr W. Sandborn & Dr S. Vermeire

Trial

Phase 2, CELEST, U-ACHIEVE

Conference

ECCO 2020

14 April, 2020 12:45

Possible new treatment targets in IBD

Conference

ECCO 2020

14 April, 2020 12:39

Multi-omics help describe CD phenotypes

Presented By

Dr B. Verstockt, University Hospital Leuven, Belgium

Conference

ECCO 2020

14 April, 2020 10:46

The positive impact of genetic data on drug development

Presented By

Prof. S. Vermeire, University Hospital Leuven, Belgium

Conference

ECCO 2020

14 April, 2020 10:45

Impact of biologicals on faecal microbiota

Presented By

C. Caenepeel, KU Leuven, Belgium

Conference

ECCO 2020

14 April, 2020 10:20

Bioactives produced by gut bacteria to modulate immune response

Presented By

R. Giri, University of Queensland, Australia

Conference

ECCO 2020

14 April, 2020 10:13

Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib

Presented By

Dr Evelyne Vinet, McGill University, Montreal, Canada

Conference

ACR 2019

4 February, 2020 23:12

Novel host-microbiome interactions in inflammatory bowel disease

Conference

ECCO 2019

9 May, 2019 20:46

Gene expression signature predicts non-response

Trial

ACT1, PURSUIT-SC, PROgECT, PURSUIT-J, UNITI

Conference

ECCO 2019

9 May, 2019 18:48

ZNF133 associated with infliximab response

Conference

ECCO 2019

9 May, 2019 17:50

Moving towards new therapeutic options

Conference

ECCO 2019

9 May, 2019 14:44